Prospective Clinical Trial Comparing Two Immunosuppressive Regimens, Tacrolimus and Mycophenolate Mofetil Versus Everolimus and Low-Dose Cyclosporine, in De Novo Renal Transplant Recipients: Results at 6 Months Follow-up

Transplantation Proceedings

Volumn 41, Issue 4, 2009, Pages 1152-1155

  Favi, E ^a   Citterio, F ^a   Spagnoletti, G ^a   Gargiulo, A ^a   Delreno, F ^a   Romagnoli, J ^a   Castagneto, M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; GRAFT REJECTION; KIDNEY FUNCTION TEST; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 65649127279     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.03.019     Document Type: Article

References (10)

1. Chapman J.R., O'Connell P.J., and Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 16 (2005) 3015
2. Pascual M., Theruvath T., Kawai T., et al. Strategies to improve long term outcomes after renal transplantation. N Engl J Med 346 (2002) 580
3. Nankivell B.J., Borrows R.J., Fung C.L.-S., et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 (2004) 557
4. Kahan B.D., and Camardo J.S. Rapamycin: clinical results and future opportunities. Transplantation 72 (2001) 1181
5. Kahan B.D. Sirolimus-based immunosuppression: present state of the art. J Nephrol 17 suppl 8 (2004) S32
6. Schuler W., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 64 (1996) 36
7. Ojo A.O., Held P.J., Port F.K., et al. Chronic renal failure after transplantation of a non renal organ. N Engl J Med 10 (2003) 349
8. Romagnoli J., Citterio F., Favi E., et al. Higher incidence of acute rejection in renal transplant recipients with low everolimus exposure. Transplant Proc 39 (2007) 1823
9. Vitko S., Tedesco H., et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4 (2004) 626
10. Tedesco H., Vitko S., et al. Twelve-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 20 (2007) 27